A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Italy- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Via Luigi Polacchi 11, 66100 Chieti, Italy
Università degli studi Gabriele D’Annunzio Chieti-Pescara Centro di Studi e tecnologie avanzate in Chieti, Italy specialises in clinical trials of conditions such as Dermatitis atopic, Partial seizures, Obesity, Type 2 diabetes mellitus, and other specialisations. This site conducts important research.
The medical center is at the forefront of research in Neurogenic Orthostatic Hypotension (nOH), a condition characterized by a significant drop in blood pressure upon standing, often associated with neurological disorders such as Multiple System Atrophy (MSA). The center's research focuses on innovative therapeutic approaches to manage and alleviate the symptoms of nOH, enhancing the quality of life for affected individuals.
Through rigorous clinical trials, the center evaluates the effectiveness and sustainability of novel treatments, contributing to the development of advanced therapeutic strategies for nOH. This research not only aims to improve patient outcomes but also to deepen the understanding of the underlying mechanisms of this complex condition.
Clinical trials currently enrolling participants at this site.
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
ItalyMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.